Dec 22 (Reuters) - AlloVir said on Friday it will discontinue three late-stage studies testing its experimental antiviral cell therapy after an independent safety board said the studies were unlikely to meet their main goals. (Reporting by Mariam Sunny in Bengaluru; Editing by Devika Syamnath)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.757 USD | +1.41% | -1.55% | +11.36% |
May. 13 | AlloVir, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Mar. 20 | North American Morning Briefing : Markets on Hold -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.36% | 85.87M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.60% | 22.1B | |
-8.89% | 18.34B | |
-41.70% | 16.59B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- ALVR Stock
- News AlloVir, Inc.
- AlloVir scraps late-stage studies testing antiviral cell therapy